$ARTH
Arch Therapeutics, Inc.

2021 Q4 Form 10-K Financial Statement

#000141057821000550 Filed on December 17, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021
Revenue $4.696K $1.570K $11.57K
YoY Change
Cost Of Revenue $16.79K $16.18K $26.28K
YoY Change
Gross Profit -$12.10K -$14.61K -$14.72K
YoY Change
Gross Profit Margin -257.58% -930.57% -127.25%
Selling, General & Admin $1.263M $1.409M $5.009M
YoY Change 41.89% 38.34% 33.9%
% of Gross Profit
Research & Development $234.6K $301.3K $1.353M
YoY Change -31.72% -6.44% -16.01%
% of Gross Profit
Depreciation & Amortization $799.00 $800.00 $2.587K
YoY Change 114.78% -45.21% -62.65%
% of Gross Profit
Operating Expenses $1.498M $1.710M $6.362M
YoY Change 21.39% 27.58% 18.88%
Operating Profit -$1.510M -$1.725M -$6.377M
YoY Change 22.37% 28.67% 19.15%
Interest Expense $40.33K -$40.33K $150.5K
YoY Change 37.8% -26.5% 712.19%
% of Operating Profit
Other Income/Expense, Net -$40.33K $136.6K
YoY Change -150.61%
Pretax Income -$1.550M -$1.765M -$6.240M
YoY Change 34.32% 26.5% 33.02%
Income Tax
% Of Pretax Income
Net Earnings -$1.550M -$1.765M -$6.240M
YoY Change 34.32% 26.5% 33.02%
Net Earnings / Revenue -33009.94% -112431.85% -53960.07%
Basic Earnings Per Share -$1.31 -$0.03
Diluted Earnings Per Share -$6.547K -$7.444K -$0.03
COMMON SHARES
Basic Shares Outstanding 237.2M 236.7M 220.0M
Diluted Shares Outstanding 220.0M

Balance Sheet

Concept 2021 Q4 2021 Q3 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.088M $2.267M $2.267M
YoY Change 23.73% 136.28% 136.28%
Cash & Equivalents $1.088M $2.267M
Short-Term Investments
Other Short-Term Assets $354.2K $307.3K $307.3K
YoY Change 79.69% 42.5% 42.5%
Inventory $1.198M $1.094M $1.094M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.536M $3.668M $3.668M
YoY Change 21.19% 71.15% 71.15%
LONG-TERM ASSETS
Property, Plant & Equipment $4.441K $5.240K $5.240K
YoY Change 6.24% 15.11% 15.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.500K $3.500K $3.500K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $7.941K $8.740K $8.740K
YoY Change 3.4% 8.54% 8.57%
TOTAL ASSETS
Total Short-Term Assets $2.536M $3.668M $3.668M
Total Long-Term Assets $7.941K $8.740K $8.740K
Total Assets $2.544M $3.676M $3.676M
YoY Change 21.13% 70.92% 70.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $748.9K $408.1K $408.1K
YoY Change 91.46% 19.31% 19.3%
Accrued Expenses $203.5K $319.5K $319.5K
YoY Change -30.78% 19.76% 19.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $1.952M $1.728M $1.728M
YoY Change 162.97% 174.89% 167.32%
LONG-TERM LIABILITIES
Long-Term Debt $1.600M $1.600M $1.600M
YoY Change -6.92% 132.27% 132.27%
Other Long-Term Liabilities $1.415M $1.375M $1.375M
YoY Change -35.9% -40.66% -40.66%
Total Long-Term Liabilities $3.015M $2.975M $2.975M
YoY Change -23.22% -1.6% -1.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.952M $1.728M $1.728M
Total Long-Term Liabilities $3.015M $2.975M $2.975M
Total Liabilities $4.967M $4.702M $4.702M
YoY Change 6.39% 28.77% 28.77%
SHAREHOLDERS EQUITY
Retained Earnings -$51.35M -$49.80M
YoY Change 14.33%
Common Stock $236.8K $48.77M
YoY Change 15.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.424M -$1.026M -$1.026M
YoY Change
Total Liabilities & Shareholders Equity $2.544M $3.676M $3.676M
YoY Change 21.13% 70.92% 70.92%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021
OPERATING ACTIVITIES
Net Income -$1.550M -$1.765M -$6.240M
YoY Change 34.32% 26.5% 33.02%
Depreciation, Depletion And Amortization $799.00 $800.00 $2.587K
YoY Change 114.78% -45.21% -62.65%
Cash From Operating Activities -$1.179M -$1.513M -$5.959M
YoY Change 4.3% 43.56% 18.12%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $3.275K
YoY Change 33.4%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$3.275K
YoY Change 33.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 0.000 7.269M
YoY Change -100.0% 89.99%
NET CHANGE
Cash From Operating Activities -$1.179M -1.513M -5.959M
Cash From Investing Activities 0.000 0.000 -3.275K
Cash From Financing Activities $0.00 0.000 7.269M
Net Change In Cash -$1.179M -1.513M 1.307M
YoY Change 1375.07% 43.56% -207.07%
FREE CASH FLOW
Cash From Operating Activities -$1.179M -$1.513M -$5.959M
Capital Expenditures $0.00 $0.00 $3.275K
Free Cash Flow -$1.179M -$1.513M -$5.962M
YoY Change 4.3% 43.56% 18.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Debt Current
DebtCurrent
0
CY2020Q3 us-gaap Debt Current
DebtCurrent
37442
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1727547
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
628460
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
0
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001537561
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Trading Symbol
TradingSymbol
ARTH
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
138858
CY2021Q3 arth Interest Payable Noncurrent
InterestPayableNoncurrent
167137
CY2020Q3 arth Interest Payable Noncurrent
InterestPayableNoncurrent
17781
CY2021Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1207475
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2316419
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2974612
CY2021Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
319464
CY2020Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
248968
CY2021Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1000000
CY2020Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiability
CY2021Q3 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiability
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
220001412
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
188051683
CY2021 dei Entity Registrant Name
EntityRegistrantName
Arch Therapeutics, Inc.
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
0
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
000-54986
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-0524102
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
235 Walnut Street
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 6
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Framingham
CY2021 dei Entity Address Country
EntityAddressCountry
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01702
CY2021 dei City Area Code
CityAreaCode
617
CY2021 dei Local Phone Number
LocalPhoneNumber
431-2313
CY2021 dei Security12g Title
Security12gTitle
Common Stock, par value $0.001 per share
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Entity Public Float
EntityPublicFloat
32000000
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
237169770
CY2021Q3 us-gaap Cash
Cash
2266639
CY2020Q3 us-gaap Cash
Cash
959309
CY2021Q3 us-gaap Inventory Net
InventoryNet
1093765
CY2020Q3 us-gaap Inventory Net
InventoryNet
967993
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
307341
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
215673
CY2021Q3 us-gaap Assets Current
AssetsCurrent
3667745
CY2020Q3 us-gaap Assets Current
AssetsCurrent
2142975
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5240
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4552
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3500
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3500
CY2021Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
8740
CY2020Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
8052
CY2021Q3 us-gaap Assets
Assets
3676485
CY2020Q3 us-gaap Assets
Assets
2151027
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
408083
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
342050
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000
CY2020Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3023058
CY2021Q3 us-gaap Liabilities
Liabilities
4702159
CY2020Q3 us-gaap Liabilities
Liabilities
3651518
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
237169770
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
193044766
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
236719770
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
193044766
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
236720
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
193045
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
48534525
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41862901
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-49796919
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43556437
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-1025674
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-1500491
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3676485
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2151027
CY2021 us-gaap Revenues
Revenues
11565
CY2020 us-gaap Revenues
Revenues
0
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
26282
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5009323
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3741020
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1353084
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1611094
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
6388689
CY2020 us-gaap Costs And Expenses
CostsAndExpenses
5352114
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-6377124
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-5352114
CY2021 us-gaap Interest Expense
InterestExpense
150531
CY2020 us-gaap Interest Expense
InterestExpense
18534
CY2021 arth Other Nonoperating Income Loss Debt Forgiveness Amount
OtherNonoperatingIncomeLossDebtForgivenessAmount
178229
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
108944
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
679271
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
136642
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
660737
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-6240482
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-4691377
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
220001412
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
188051683
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-807297
CY2020 us-gaap Profit Loss
ProfitLoss
-4691377
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
932728
CY2020 arth Stock And Warrants Issued During Period Net Of Issuance Costs Value New Issues
StockAndWarrantsIssuedDuringPeriodNetOfIssuanceCostsValueNewIssues
2167162
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
898293
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-1500491
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-1500491
CY2021 us-gaap Profit Loss
ProfitLoss
-6240482
CY2021 arth Stock And Warrants Issued During Period Net Of Issuance Costs Value New Issues
StockAndWarrantsIssuedDuringPeriodNetOfIssuanceCostsValueNewIssues
6219233
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
496066
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2180329
CY2021 arth Proceeds Form Issued Common Stock And Warrants
ProceedsFormIssuedCommonStockAndWarrants
6219233
CY2020 arth Proceeds Form Issued Common Stock And Warrants
ProceedsFormIssuedCommonStockAndWarrants
2167162
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
932728
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7269233
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3826190
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1307330
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1221020
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
959309
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-1025674
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-6240482
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-4691377
CY2021 us-gaap Depreciation
Depreciation
2587
CY2020 us-gaap Depreciation
Depreciation
6926
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
496066
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
898293
CY2021 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-108944
CY2020 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-679271
CY2021 us-gaap Inventory Write Down
InventoryWriteDown
181988
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
60385
CY2021 arth Gains Losses On Forgiveness Of Debt
GainsLossesOnForgivenessOfDebt
178229
CY2020 arth Gains Losses On Forgiveness Of Debt
GainsLossesOnForgivenessOfDebt
0
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
307760
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
681731
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
91668
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-147032
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
66033
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-191505
CY2021 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
151285
CY2020 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
70496
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
86493
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5958628
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5044755
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3275
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2455
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3275
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2455
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1050000
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
550000
CY2021 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
0
CY2020 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
176300
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2266639
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
959309
CY2021 arth Issuance Of Restricted Stock
IssuanceOfRestrictedStock
0
CY2020 arth Issuance Of Restricted Stock
IssuanceOfRestrictedStock
965
CY2021 arth Issuance Of Restricted Stock For Services
IssuanceOfRestrictedStockForServices
103750
CY2020 arth Issuance Of Restricted Stock For Services
IssuanceOfRestrictedStockForServices
93500
CY2021 arth Series J Warrants Cost
SeriesJWarrantsCost
0
CY2020 arth Series J Warrants Cost
SeriesJWarrantsCost
219737
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</p>
CY2020Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.</p>
CY2021Q3 arth Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
0
CY2020Q3 arth Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
39000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
0
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
39000
CY2021 us-gaap Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Derivative Liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, <i style="font-style:italic;">Derivatives and Hedging</i>. Warrants classified as equity are recorded at fair value as of the date of issuance on the Company’s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and will be revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate.</p>
CY2021Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
57812
CY2020Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
18518
CY2021Q3 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
62946
CY2020Q3 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
16497
CY2021Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15147957
CY2020Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
13521819
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33756
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
30481
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
28516
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25929
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5240
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4552
CY2021 us-gaap Depreciation
Depreciation
2587
CY2020 us-gaap Depreciation
Depreciation
6926
CY2021Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
10022020
CY2020Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8451214
CY2021Q3 arth Deferred Tax Assets Capitalized Expenditures
DeferredTaxAssetsCapitalizedExpenditures
1703849
CY2020Q3 arth Deferred Tax Assets Capitalized Expenditures
DeferredTaxAssetsCapitalizedExpenditures
1782185
CY2021Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
946158
CY2020Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
928734
CY2021Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2352432
CY2020Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2321519
CY2021Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
2740
CY2020Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
3152
CY2021Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15147957
CY2020Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13521819
CY2021Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0580
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0708
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Life Insurance
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLifeInsurance
0.0001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Life Insurance
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLifeInsurance
0.0001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.0029
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.0051
CY2021 arth Effective Income Tax Rate Reconciliation Nondeductible Expense Fair Value Of Derivative Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueOfDerivativePercent
0.0037
CY2020 arth Effective Income Tax Rate Reconciliation Nondeductible Expense Fair Value Of Derivative Percent
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFairValueOfDerivativePercent
0.0304
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.0060
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.0000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0141
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0051
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.2606
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.3111
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
37018000
CY2020Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
31119000
CY2021Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
36033000
CY2020Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
30737000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1626000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1459000
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
249571
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
844194
CY2020Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
967993
CY2021Q3 us-gaap Inventory Net
InventoryNet
1093765
CY2020Q3 us-gaap Inventory Net
InventoryNet
967993
CY2016Q3 arth Shelf Registration Statement Maximum Amount Authorized
ShelfRegistrationStatementMaximumAmountAuthorized
50000000
CY2021Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
1628113
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
108944
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
679271
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7944
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1944
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0013
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0285
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.36
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
18248346
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y7M2D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
79330
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7375000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.12
CY2021 arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
724332
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.44
CY2021 arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24899014
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.29
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P1Y9M29D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
140151
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
18814908
CY2021 arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
0.35
CY2021 arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P2Y2M1D
CY2021 arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue
17122
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
24899014
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.29
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P1Y9M29D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
140151
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2018Q3 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
38400
CY2019Q3 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
39600
CY2020Q3 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
42000
CY2020Q3 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
42000
CY2021Q3 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
42000
CY2021Q3 arth Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
0
CY2020Q3 arth Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
39000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
0
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
39000

Files In Submission

Name View Source Status
0001410578-21-000550-index-headers.html Edgar Link pending
0001410578-21-000550-index.html Edgar Link pending
0001410578-21-000550.txt Edgar Link pending
0001410578-21-000550-xbrl.zip Edgar Link pending
arth-20210930.xsd Edgar Link pending
arth-20210930x10k.htm Edgar Link pending
arth-20210930x10k_htm.xml Edgar Link completed
arth-20210930xex23d1.htm Edgar Link pending
arth-20210930xex31d1.htm Edgar Link pending
arth-20210930xex31d2.htm Edgar Link pending
arth-20210930xex32d1.htm Edgar Link pending
arth-20210930xex4d1.htm Edgar Link pending
arth-20210930_cal.xml Edgar Link unprocessable
arth-20210930_def.xml Edgar Link unprocessable
arth-20210930_lab.xml Edgar Link unprocessable
arth-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending